Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more
Citius Oncology, Inc. (CTOR) - Total Liabilities
Latest total liabilities as of December 2025: $51.56 Million USD
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has total liabilities worth $51.56 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Citius Oncology, Inc. - Total Liabilities Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Citius Oncology, Inc. Competitors by Total Liabilities
The table below lists competitors of Citius Oncology, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Victory Square Technologies Inc
OTCQB:VSQTF
|
USA | $13.67 Million |
|
Belysse Group N.V.
BR:BELYS
|
Belgium | €219.63 Million |
|
Otto Energy Limited
PINK:OTTEF
|
USA | $11.15 Million |
|
Legacy Minerals Holdings Ltd
AU:LGM
|
Australia | AU$658.15K |
|
Viva Gold Corp
OTCQB:VAUCF
|
USA | $218.32K |
|
Ecocera Optronics Co., Ltd.
TWO:6597
|
Taiwan | NT$360.30 Million |
|
Global Oil & Gas Limited
PINK:BAKPF
|
USA | $285.67K |
Liability Composition Analysis (2022–2025)
This chart breaks down Citius Oncology, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Citius Oncology, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Citius Oncology, Inc. (2022–2025)
The table below shows the annual total liabilities of Citius Oncology, Inc. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $56.08 Million | +46.69% |
| 2024-09-30 | $38.23 Million | +72.21% |
| 2023-09-30 | $22.20 Million | +245.63% |
| 2022-09-30 | $6.42 Million | -- |